This site is intended for healthcare professionals outside the US.

BOLERO-2

Final overall survival results

“AFINITOR (everolimus) plus exemestane demonstrated a 4.4-month difference in OS vs exemestane monotherapy”
  • No statistically significant difference in OS (31.0 months vs 26.6 months, respectively, HR=0.89; 95% CI, 0.73-1.10; log rank P=0.14)1
  • AFINITOR plus exemestane demonstrated median OS duration of 31 months (95% CI, 28.0-34.6) compared with 26.6 months (95% CI, 22.6-33.1) for exemestane alone1
  • No statistically significant difference in OS after a median duration of 39 months (HR=0.89; 95% CI, 0.73-1.10; log rank P=0.14)1
  • 2.6 years (31 months) is the longest reported median OS duration in a phase 3 clinical trial in HR+, HER2– advanced breast cancer1-4*
  • AFINITOR plus exemestane demonstrated median OS duration of 31 months (95% CI, 28.0-34.6) compared with 26.6 months (95% CI, 22.6-33.1) for exemestane alone1,5
Abbreviations:
aBC, advanced breast cancer; BOLERO-2, Breast Cancer Trials of Oral Everolimus-2; CI, confidence interval; HR, hazard ratio; HR+, hormone receptor-positive; OS, overall survival; PFS, progression-free survival.
Reference:
1. AFINITOR [summary of product characteristics]. Novartis Pharma AG; 2017.